First drug trial launched for devastating brain disease
NCT ID NCT05757141
Summary
This study is testing a new drug called fosigotifator for vanishing white matter disease, a rare and serious genetic brain disorder. It will enroll about 50 adults and children to see if the drug is safe, how the body handles it, and if it might help control the disease. This is an early-stage study, so the main goal is to gather information for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VANISHING WHITE MATTER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC, locatie VUmc /ID# 270955
RECRUITINGAmsterdam, North Holland, 1081 HV, Netherlands
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Massachusetts General Hospital /ID# 270960
RECRUITINGBoston, Massachusetts, 02114, United States
-
McGill University Health Centre - Glen Site
RECRUITINGMontreal, Quebec, H3H2L9, Canada
-
University of Utah /ID# 255624
RECRUITINGSalt Lake City, Utah, 84112-5339, United States
Conditions
Explore the condition pages connected to this study.